

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and a Limited Waiver under 18 U.S.C. §208(b)(3)

Jeffrey S. Borer, M.D.

Committee: Anti-Infective Drugs Advisory Committee

Meeting Date: March 6, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to New Drug Application (NDA) 21-572/S-008, Cubicin (daptomycin for injection 500 mg/vial), manufactured for Cubist Pharmaceuticals by Integrated Commercialization Solutions, for the proposed indication for the treatment of Staphylococcus aureus bacteremia, including those with known or suspected endocarditis caused by methicillin-susceptible and methicillin-resistant strains, I am eligible to receive a limited waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Speaker's Bureau	Competitor	From \$10,001 to \$50,000 per year.
Unrelated Consulting	University which is supported by a competing firm	Less than \$10,001 per year.
Unrelated Consulting	Competitor	Less than \$10,001 per year.
Unrelated Consulting	Competitor	Greater than \$50,000 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

//S//
Signature of SGE

2/6/06
Date